GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 17.15 Billion KRW | -12.74% |
| 2022 | 19.66 Billion KRW | 6.88% |
| 2021 | 18.39 Billion KRW | 3.57% |
| 2020 | 17.76 Billion KRW | 22.64% |
| 2019 | 14.48 Billion KRW | 16.95% |
| 2018 | 12.38 Billion KRW | 750.8% |
| 2017 | 1.45 Billion KRW | -93.4% |
| 2016 | 22.06 Billion KRW | 1793.89% |
| 2015 | 1.16 Billion KRW | 42.78% |
| 2014 | 816.12 Million KRW | -69.84% |
| 2013 | 2.7 Billion KRW | -74.39% |
| 2012 | 10.56 Billion KRW | 225.07% |
| 2011 | 3.25 Billion KRW | 32.12% |
| 2010 | 2.46 Billion KRW | -76.19% |
| 2009 | 10.33 Billion KRW | 320.05% |
| 2008 | 2.46 Billion KRW | -66.0% |
| 2007 | 7.23 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 18.34 Billion KRW | 6.93% |
| 2024 Q2 | 21.49 Billion KRW | 2.08% |
| 2023 Q1 | 16.83 Billion KRW | -14.37% |
| 2023 Q2 | 7.68 Billion KRW | -54.35% |
| 2023 FY | 17.15 Billion KRW | -12.74% |
| 2023 Q3 | 9.22 Billion KRW | 20.02% |
| 2023 Q4 | 17.15 Billion KRW | 86.0% |
| 2022 Q1 | 18.05 Billion KRW | -1.86% |
| 2022 Q3 | 19.87 Billion KRW | -2.95% |
| 2022 Q4 | 19.66 Billion KRW | -1.05% |
| 2022 FY | 19.66 Billion KRW | 6.88% |
| 2022 Q2 | 20.47 Billion KRW | 13.41% |
| 2021 FY | 18.39 Billion KRW | 3.57% |
| 2021 Q1 | 18.11 Billion KRW | 1.95% |
| 2021 Q2 | 22.36 Billion KRW | 23.48% |
| 2021 Q3 | 26.98 Billion KRW | 20.67% |
| 2021 Q4 | 18.39 Billion KRW | -31.82% |
| 2020 FY | 17.76 Billion KRW | 22.64% |
| 2020 Q2 | 3.53 Billion KRW | -26.49% |
| 2020 Q3 | 2.6 Billion KRW | -26.47% |
| 2020 Q4 | 17.76 Billion KRW | 582.96% |
| 2020 Q1 | 4.81 Billion KRW | -66.78% |
| 2019 Q1 | 16.89 Billion KRW | 36.35% |
| 2019 FY | 14.48 Billion KRW | 16.95% |
| 2019 Q3 | 17.03 Billion KRW | 1.66% |
| 2019 Q2 | 16.75 Billion KRW | -0.8% |
| 2019 Q4 | 14.48 Billion KRW | -14.95% |
| 2018 Q3 | 12.19 Billion KRW | 3.8% |
| 2018 Q4 | 12.38 Billion KRW | 1.56% |
| 2018 Q2 | 11.75 Billion KRW | 675.39% |
| 2018 Q1 | 1.51 Billion KRW | 4.08% |
| 2018 FY | 12.38 Billion KRW | 750.8% |
| 2017 FY | 1.45 Billion KRW | -93.4% |
| 2017 Q4 | 1.45 Billion KRW | -93.64% |
| 2017 Q3 | 22.88 Billion KRW | 1.93% |
| 2017 Q2 | 22.44 Billion KRW | 0.54% |
| 2017 Q1 | 22.32 Billion KRW | 1.18% |
| 2016 Q2 | 21.13 Billion KRW | 1549.96% |
| 2016 FY | 22.06 Billion KRW | 1793.89% |
| 2016 Q4 | 22.06 Billion KRW | 2.31% |
| 2016 Q3 | 21.57 Billion KRW | 2.08% |
| 2016 Q1 | 1.28 Billion KRW | 9.9% |
| 2015 FY | 1.16 Billion KRW | 42.78% |
| 2015 Q4 | 1.16 Billion KRW | -18.43% |
| 2015 Q3 | 1.42 Billion KRW | 17.96% |
| 2015 Q2 | 1.21 Billion KRW | 42.35% |
| 2015 Q1 | 850.74 Million KRW | 4.24% |
| 2014 Q3 | 3.22 Billion KRW | -5.05% |
| 2014 Q2 | 3.4 Billion KRW | 12.9% |
| 2014 Q1 | 3.01 Billion KRW | 11.34% |
| 2014 FY | 816.12 Million KRW | -69.84% |
| 2014 Q4 | 816.12 Million KRW | -74.73% |
| 2013 FY | 2.7 Billion KRW | -74.39% |
| 2013 Q4 | 2.7 Billion KRW | 0.96% |
| 2013 Q3 | 2.68 Billion KRW | -3.1% |
| 2013 Q2 | 2.76 Billion KRW | -43.64% |
| 2013 Q1 | 4.9 Billion KRW | -53.55% |
| 2012 Q4 | 10.56 Billion KRW | 0.0% |
| 2012 FY | 10.56 Billion KRW | 225.07% |
| 2012 Q1 | 9.26 Billion KRW | 0.0% |
| 2011 FY | 3.25 Billion KRW | 32.12% |
| 2011 Q3 | 2.46 Billion KRW | 0.0% |
| 2011 Q2 | 2.46 Billion KRW | 0.0% |
| 2011 Q1 | 2.46 Billion KRW | 0.0% |
| 2010 Q1 | 10.49 Billion KRW | 0.0% |
| 2010 FY | 2.46 Billion KRW | -76.19% |
| 2010 Q3 | 2.46 Billion KRW | -76.96% |
| 2010 Q2 | 10.67 Billion KRW | 1.69% |
| 2009 FY | 10.33 Billion KRW | 320.05% |
| 2009 Q3 | 10.16 Billion KRW | 313.33% |
| 2009 Q2 | 2.46 Billion KRW | -33.93% |
| 2009 Q1 | 3.72 Billion KRW | 51.35% |
| 2008 Q1 | 6.79 Billion KRW | -6.11% |
| 2008 Q2 | 7.52 Billion KRW | 10.8% |
| 2008 Q3 | 7.1 Billion KRW | -5.68% |
| 2008 Q4 | 2.46 Billion KRW | -65.35% |
| 2008 FY | 2.46 Billion KRW | -66.0% |
| 2007 Q2 | 3 Billion KRW | 0.0% |
| 2007 FY | 7.23 Billion KRW | 0.0% |
| 2007 Q4 | 7.23 Billion KRW | 141.19% |
| 2007 Q3 | 3 Billion KRW | 0.0% |
| 2007 Q1 | 3 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | -464.514% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | 98.66% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | 97.63% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -466.746% |
| Green Cross Corporation | 724.02 Billion KRW | 97.63% |
| Celltrion, Inc. | 1890.42 Billion KRW | 99.092% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 99.101% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | 16.594% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | 90.362% |
| Prestige BioPharma Limited | 89.66 Billion KRW | 80.863% |